Norian's SRS injectable bone mineral substitute entering clinicals.
This article was originally published in The Gray Sheet
Executive SummaryNORIAN'S SKELETAL REPAIR SYSTEM INJECTABLE BONE MINERAL SUBSTITUTE is entering U.S. clinical trials for treatment of distal radius wrist fractures. The 12-center randomized controlled study, cleared under an investigational device exemption, will include up to 324 patients ranging from age 45 to 80 at twelve different hospitals.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.
How do notified bodies ensure that their personnel, and the teams they allocate for conformity assessment of medical devices, have the precise knowledge and expertise needed? A new EU document gives guidance on this.